BioBehavioral Diagnostics

BioBehavioral Diagnostics (BioBDx), founded in 2003, developed a quantitative assessment platform for neurobiological disorders, most notably Attention-Deficit/Hyperactivity Disorder (ADHD). The company's core technology was invented by Martin H. Teicher, M.D., Ph.D., the director of the Developmental Biopsychiatry Research Program at McLean Hospital, an affiliate of Harvard Medical School. BioBDx operated in the medical diagnostics market, serving clinicians, pediatricians, neurologists, and psychiatrists. Revenue was generated through the sale of its diagnostic system to these healthcare professionals. After raising approximately $38.5M in funding from investors like Sevin Rosen Funds and Tullis Health Investors, the company was acquired by Pearson, a global education and assessment company, in August 2013, marking Pearson's strategic entry into the healthcare market.

The company's flagship product is the Quotient ADHD System, an FDA-cleared device that provides an objective measurement of the core symptoms of ADHD: hyperactivity, inattention, and impulsivity. This system addresses the subjectivity often found in traditional ADHD assessments, which typically rely on checklists and interviews. The Quotient test involves a computerized, game-like task lasting 15-20 minutes. During the test, advanced motion-tracking technology with an infrared sensor records a patient's micro-movements, while the software analyzes the accuracy of their responses to visual cues. Proprietary algorithms then score the patterns of motion, response accuracy, and fluctuations in attention. The resulting report offers clinicians quantitative data to aid in diagnosis, determine symptom severity, and monitor the effectiveness of treatments like medication.

Keywords: ADHD diagnostics, neurobiological assessment, Quotient ADHD System, objective ADHD testing, motion tracking technology, medical diagnostics, behavioral health technology, Pearson Clinical Assessment, Martin Teicher, continuous performance task, hyperactivity measurement, inattention assessment, impulsivity analysis, FDA-cleared medical device, clinical decision support, psychiatric diagnostic tools, pediatric neurology, neurobehavioral disorder, healthcare technology, diagnostic systems